ํด๋ก๋ฅด๋์์ ํญ์๋ ๋ฐ ํด๋ฆฌ๋๋
ํด๋ก๋ฅด๋์์ ํญ์๋๋ ์ฃผ๋ก ํญ๋ถ์ ๋ฐ ๊ฒฝ๋ฏธํ ์ง์ ํจ๊ณผ๋ฅผ ์ํด ์ฌ์ฉ๋๋ ์ง์์ฑ **๋ฒค์กฐ๋์์ ํ๊ณ ์ฝ๋ฌผ**์ ๋๋ค. ํด๋ฆฌ๋๋ ๋ธ๋กฌํ๋ฌผ์ ์์ฅ๊ด ์ด๋๊ณผ ๊ฒฝ๋ จ์ ๊ฐ์์ํค๋ ํฉ์ฑ 4๊ธ ์๋ชจ๋ **ํญ๋ฌด์ค์นด๋ฆฐ(ํญ์ฝ๋ฆฐ)** ์ ์ ์ ๋๋ค. ์์ํ์์ ์ด ์ฝ๋ฌผ๋ค์ ๋จ๋ ์ผ๋ก ๋๋ ๋ณ์ฉํ์ฌ ์ฌ์ฉ๋๊ธฐ๋ ํฉ๋๋ค: * **ํด๋ก๋ฅด๋์์ ํญ์๋ ๋จ๋ **: ๋ฐ๋ ค๊ฒฌ์ ์์ ๊ณตํฌ์ฆ์ด๋ ๋ฐ๋ ค๋ฌ์ ๊ณ ์์ด ๊ฐ ๊ณต๊ฒฉ์ฑ ๋ฐ ์๋ณ ์คํ๋ ์ด์ ๊ฐ์ ํ๋ ์ฅ์ ์ ๋ณด์กฐ ์๋ฒ์ผ๋ก ์ฌ์ฉ๋ฉ๋๋ค. * **ํด๋ก๋ฅด๋์์ ํญ์๋ + ํด๋ฆฌ๋๋ (Libraxยฎ)**: ์ด ๋ณตํฉ์ ๋ ๋ฐ๋ ค๊ฒฌ์ **๊ณผ๋ฏผ์ฑ ๋์ฅ ์ฆํ๊ตฐ(IBS)**๊ณผ ๊ฐ์ ์คํธ๋ ์ค ์ ๋ฐ์ฑ ์์ฅ๊ด ์งํ์ ์น๋ฃํ๋ ๋ฐ ๋ ํนํ ์์น๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ค์ถ์ฑ ๋ถ์ ์์(ํด๋ก๋ฅด๋์์ ํญ์๋)์ ๋ง์ด์ฑ ์์ฅ ๊ฒฝ๋ จ(ํด๋ฆฌ๋๋)์ ๋์์ ํด๊ฒฐํฉ๋๋ค. > **์์ ํ**: ํด๋ฆฌ๋๋์ 4๊ธ ์๋ฏผ์ด๊ธฐ ๋๋ฌธ์ ํ์ก-๋ ์ฅ๋ฒฝ์ ์ฝ๊ฒ ํต๊ณผํ์ง ๋ชปํ์ฌ, ์ํธ๋กํ์์ ํํ ๋ณผ ์ ์๋ ์ค์ถ์ฑ ํญ์ฝ๋ฆฐ ๋ถ์์ฉ์ ํผํ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : The combination product exerts its effects through two distinct mechanisms targeting the central nervous system and the peripheral gastrointestinal tract: * **Chlordiazepoxide (Anxiolytic/Sedative)**: Binds to the benzodiazepine allosteric site on the **GABA-A receptor** complex in the CNS โ enhances the affinity of the receptor for the inhibitory neurotransmitter **gamma-aminobutyric acid (GABA)** โ increases the frequency of chloride channel openings โ neuronal hyperpolarization. This dampens activity in the limbic system, thalamus, and hypothalamus, producing anxiolytic, muscle relaxant, and anticonvulsant effects. * **Clidinium (Antispasmodic)**: Acts as a competitive antagonist at **muscarinic acetylcholine receptors** (primarily M3 receptors in the gut) โ inhibits parasympathetic nerve impulses โ significantly reduces gastrointestinal smooth muscle spasms, motility, and gastric acid secretion.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- As an anxiolytic ยท 0.5-1 mg/kg ยท PO ยท q12-24h ยท Chlordiazepoxide alone
- Behavior indications (thunderstorm/noise phobias) ยท 2.2-6.6 mg/kg ยท PO ยท as needed ยท Chlordiazepoxide alone; start low
- Symptomatic treatment of irritable bowel syndrome ยท 0.1-0.25 mg/kg of clidinium or 1-2 capsules ยท PO ยท two times to three times a day ยท Discontinued in a few days ยท Using the combination product (e.g., Librax). Give when abdominal pain or diarrhea first noticed or if stressful conditions are encountered.
- Symptomatic treatment of irritable bowel syndrome ยท 0.44-1.1 mg/kg of clidinium ยท PO ยท two to three times a day ยท 1 day to 2 weeks (some require long-term treatment at 1-2 doses per day) ยท Using the combination product (e.g., Librax). Use at first signs of cramping or abdominal pain.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity to benzodiazepines or antimuscarinics
- Coma, shock, or significant respiratory depression
- Aggressive patients (may disinhibit bite inhibition and worsen aggression)
- Tachycardia secondary to thyrotoxicosis or cardiac insufficiency
- Myocardial ischemia
- Gastrointestinal obstructive disease or paralytic ileus
- Severe ulcerative colitis
- Obstructive uropathy
- Myasthenia gravis
- Known or suspected GI infections (may prolong retention of toxins/pathogens)
์ด์๋ฐ์
- Paradoxical CNS excitement or agitation (especially in dogs)
- Variable sedation and lethargy
- Behavioral changes (irritability, aberrant demeanor in cats)
- Potential hepatotoxicity (idiosyncratic hepatic failure reported with oral diazepam in cats; unknown if chlordiazepoxide shares this risk)
- Dry mouth (xerostomia)
- Constipation or dysphagia
- Urinary retention or hesitancy
- Tachycardia (at higher doses) or initial bradycardia
์ฝ๋ฌผ ์ํธ์์ฉ
- Digoxin ยท Pharmacologic effects of digoxin may be increased; clidinium may also increase serum levels of slow-dissolving digoxin.
- CNS Depressants (barbiturates, opiates, anesthetics) ยท Additive CNS depression and sedative effects.
- Probenecid ยท May interfere with benzodiazepine metabolism in the liver, causing increased or prolonged effects.
- Rifampin ยท May induce hepatic microsomal enzymes and decrease the pharmacologic effects of benzodiazepines.
- Cimetidine ยท May decrease the metabolism of chlordiazepoxide, leading to excessive sedation.
- Erythromycin ยท May decrease the metabolism of chlordiazepoxide, leading to excessive sedation.
- Fluoxetine ยท May decrease the metabolism of chlordiazepoxide, leading to excessive sedation.
- Isoniazid ยท May decrease the metabolism of chlordiazepoxide, leading to excessive sedation.
- Ketoconazole ยท May decrease chlordiazepoxide metabolism. Additionally, increased gastric pH from clidinium may decrease GI absorption of ketoconazole (administer clidinium 2 hours after ketoconazole).
- Metoprolol ยท May decrease the metabolism of chlordiazepoxide, leading to excessive sedation.
- Propranolol ยท May decrease the metabolism of chlordiazepoxide, leading to excessive sedation.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (reduction in anxiety, resolution of GI spasms/diarrhea)
- Adverse effects (excessive sedation, paradoxical excitement, anticholinergic signs)
- Baseline and periodic liver function tests in cats (due to idiosyncratic hepatotoxicity risks associated with oral benzodiazepines)
๊ณผ์ฉ๋
Overdoses of chlordiazepoxide alone are generally limited to significant **CNS depression** (confusion, coma, decreased reflexes). Hypotension, respiratory depression, and cardiac arrest are possible but rare. **Treatment**: * Standard protocols for acute oral toxicity (gastric decontamination, binding agents like activated charcoal). * Supportive systemic measures (fluids, cardiovascular support). * **Flumazenil** may be considered as a specific reversal agent for severe benzodiazepine-induced CNS depression. * Analeptic agents (CNS stimulants like caffeine) are generally not recommended.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.